Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines.

Berman, Jonathan; Brown, Tracey; Dow, Geoffrey; Toovey, Stephen

Berman, Jonathan; Brown, Tracey; Dow, Geoffrey; Toovey, Stephen.

Afiliação

Berman J; Fast-Track Drugs & Biologics, North Potomac, MD, 20878, USA.
Brown T; Clinical Network Services Pty Ltd, 88/4 Jephson Road, Toowong, 4066, Queensland, Australia.
Dow G; 60°Pharmaceuticals LLC, 1025 Connecticut Ave NW, Suite 1000, Washington, DC, 20036, USA. geoffdow@60degreespharma.com.
Toovey S; Pegasus Research, 4103, Bottmingen, Switzerland.

Malar J ; 17(1): 407, 2018 Nov 06.

Article em En | MEDLINE | ID: mdl-30400893

Assuntos

Aminoquinolinas/efeitos adversos; Antimaláricos/efeitos adversos; Malária Vivax/prevenção & controle; Primaquina/efeitos adversos; Animais; Humanos; Macaca mulatta

Palavras-chave

8-aminoquinoline; Brain-stem; Malaria; Monkeys; Neurohistopathology; Neurotoxicity; Pamaquine; Pentaquine; Plasmocid; Primaquine; Tafenoquine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Primaquina / Malária Vivax / Aminoquinolinas / Antimaláricos Tipo de estudo: Diagnostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Revista: Malar J Assunto da revista: MEDICINA TROPICAL Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google